Patents by Inventor Angela M. Cacace
Angela M. Cacace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12180478Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: July 27, 2022Date of Patent: December 31, 2024Assignees: Roche Innovation Center Copenhagen A/SInventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
-
Publication number: 20240217962Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.Type: ApplicationFiled: October 13, 2023Publication date: July 4, 2024Inventors: Andrew P. CREW, Michael BERLIN, Angela M. CACACE, Julian T. CHANDLER
-
Patent number: 11912699Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.Type: GrantFiled: July 17, 2020Date of Patent: February 27, 2024Assignee: ARVINAS OPERATIONS, INC.Inventors: Andrew P. Crew, Michael Berlin, Angela M. Cacace, Julian T. Chandler
-
Patent number: 11761951Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.Type: GrantFiled: February 4, 2016Date of Patent: September 19, 2023Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Niels Fisker Nielsen, Dong LI, Jeffrey M. Brown, Stephen E. Mercer, Marianne Lerbech Jensen
-
Publication number: 20230193260Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: July 27, 2022Publication date: June 22, 2023Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. OLSON, Angela M. Cacace, Jere E. Meredith, JR., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
-
Publication number: 20220315575Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.Type: ApplicationFiled: July 17, 2020Publication date: October 6, 2022Inventors: Andrew P. Crew, Michael Berlin, Hanqing Dong, Alexey Ishchenko, Angela M. Cacace, Julian T. Chandler
-
Patent number: 11447775Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: January 11, 2019Date of Patent: September 20, 2022Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
-
Patent number: 11359197Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 2, 2021Date of Patent: June 14, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
-
Publication number: 20220143064Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: July 2, 2021Publication date: May 12, 2022Applicant: F. Hoffmann-La Roche AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Publication number: 20220119811Abstract: The present disclosure relates to antisense oligonucleotides, which target Alpha-synuclein (SNCA) transcript in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder such as a synucleinopathy.Type: ApplicationFiled: January 11, 2019Publication date: April 21, 2022Applicant: Roche Innovation Center Copenhagen A/SInventors: Peter HAGEDORN, Richard E. OLSON, Angela M. CACACE, Marianne Lerbach JENSEN, Jeffrey M. BROWN, Jere E. MEREDITH, JR., Annapurna PENDRI, Ivar M. MCDONALD, Martin GILL
-
Patent number: 11077132Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: August 3, 2021Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Publication number: 20210180065Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: February 2, 2021Publication date: June 17, 2021Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
-
Publication number: 20200362347Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: January 11, 2019Publication date: November 19, 2020Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
-
Publication number: 20200354720Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: January 11, 2019Publication date: November 12, 2020Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
-
Patent number: 10799523Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: October 13, 2020Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
-
Publication number: 20190383797Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.Type: ApplicationFiled: February 4, 2016Publication date: December 19, 2019Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER, Marianne Lerbech JENSEN
-
Publication number: 20180161356Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: February 4, 2016Publication date: June 14, 2018Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Publication number: 20160237427Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: February 4, 2016Publication date: August 18, 2016Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Marianne Lerbech JENSEN, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER
-
Publication number: 20040214317Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, neurological conditions, and diseases or disorders related to the brain are illustrated.Type: ApplicationFiled: November 13, 2003Publication date: October 28, 2004Inventors: Peter Battaglino, John N. Feder, Gabriel Mintier, Thomas C. Nelson, Chandra S. Ramanathan, Ryan Westphal, Angela M. Cacace, Lauren E. Barber, Donald R. Hawken, Michael G. Kornacker
-
Publication number: 20040147732Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, neurological conditions, urological conditions, and diseases or disorders related to the brain and testes are illustrated. Additional methods for treating, diagnosing, preventing, and screening for disorders associated with Alzheimer's disease, proliferative lung disorders, and disorders associated with aberrant NFkB and/or E-selectin expression and/or function are illustrated.Type: ApplicationFiled: October 7, 2003Publication date: July 29, 2004Inventors: John N. Feder, Gabriel Mintier, Chandra S. Ramanathan, Donald R. Hawken, Angela M. Cacace, Kelly L. Bennett